ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.05
+3.65%Next report
Analyst consensus
- Next report date
- Oct 26, 2026
- EPS estimate
- -$0.39
- Revenue estimate
- —
Latest reported
- Last report date
- Oct 26, 2026
- EPS actual
- -$0.45
- EPS estimate
- -$0.36
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +10.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.50
- PT range
- $5.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 26, 2026 | -$0.39 | -$0.35 | Beat 9.93% | — |
| Aug 12, 2026 | -$0.36 | -$0.45 | Miss -25.23% | — |
| May 12, 2026 | -$0.40 | -$0.33 | Beat 18.07% | — |
| Mar 26, 2026 | -$0.50 | -$0.41 | Beat 18.00% | — |
| Nov 12, 2025 | -$0.63 | -$0.44 | Beat 30.16% | — |
| Aug 12, 2025 | -$0.54 | -$0.68 | Miss -25.93% | — |
| Mar 27, 2025 | -$0.47 | -$0.62 | Miss -31.91% | — |
| Aug 13, 2024 | -$0.28 | -$0.34 | Miss -21.43% | — |
| Nov 14, 2022 | -$0.27 | -$0.26 | Beat 3.70% | — |
| Aug 15, 2022 | -$0.24 | -$0.25 | Miss -4.17% | — |
| May 16, 2022 | -$0.17 | -$0.23 | Miss -35.29% | — |
| Nov 15, 2021 | -$0.21 | -$0.10 | Beat 52.38% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 29, 2027